Why Sanofi Stock Is Falling Thursday - Sanofi (NASDAQ:SNY)
Sanofi said Dupixent sales rose 37.6% to €5.154 billion, while vaccines sales fell 4.7% to €1.15 billion. Beyfortus sales increased 54.2% to €108 million. Adjusted EPS was €2.09 per share ($1.21 per ADS), above consensus. Sanofi raised Dupixent and 2026 sales outlook but warned second-half growth may moderate; SNY shares were down 5.65% to $42.31.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term expectations using the specific fiscal 2026 sales figure, the updated CER growth rate, and the stated expectation of slower growth in the second half plus fewer margin and buyback boosts.
Market read
A guidance update with explicit sales/EPS and a portfolio review narrative explains the stock’s sharp drop and sets a new expectation path for 2H growth and margins.
What to watch
Second-half moderation may be driven by tougher comps and fewer one-time benefits, which could be less damaging if core demand remains strong and pipeline cuts are reallocations rather than value destruction.
Background
The piece attributes Sanofi’s decline to a mix of strong Dupixent performance and weaker vaccine sales, alongside a CEO-led portfolio review and R&D discipline.
Ticker impact
Sanofi guided fiscal 2026 sales to $55.789B, raised Dupixent and 2030 outlook, and flagged slower second-half growth plus pipeline halts.
Bias to continued volatility or downside if investors focus on slower 2H growth and R&D/pipeline setbacks despite Dupixent beats.
The article cites EPS beat and higher Dupixent sales expectations, but also signals tougher R&D discipline, program discontinuations, fewer margin one-offs, and moderated growth in the second half.
Market effects
Highlights pharma investor focus on pipeline execution and margin one-offs, not just top-line growth.
Primarily impacts US-listed large-cap pharma sentiment; may spill over to European pharma peers via read-across on pipeline discipline.
Dupixent and Beyfortus demand signals reinforce global respiratory/immunology growth narratives while vaccine weakness tempers broader vaccine optimism.
Counterpoint
The raised Dupixent and 2030 sales targets plus EPS beat suggest the selloff may overreact to pipeline review details.
Key entities
- companySanofi
US-listed pharma company reporting Dupixent and vaccine sales trends, raising outlook, and signaling pipeline discontinuations and slower 2H growth.
- productDupixent
Sanofi’s immunology drug with reported 37.6% sales growth and raised 2030 sales expectations.
- productBeyfortus
Respiratory product with 54.2% sales growth cited as benefiting from expanded geographic availability.
